Scarica l'app Stockscreener
2.725
3.02%
-0.085
Dopo l'orario di chiusura:
2.73
0.005
+0.18%
Precedente Chiudi:
$2.81
Aprire:
$2.84
Volume 24 ore:
320.25K
Relative Volume:
1.49
Capitalizzazione di mercato:
$270.94M
Reddito:
$4.60M
Utile/perdita netta:
$-82.31M
Rapporto P/E:
-3.3224
EPS:
-0.8202
Flusso di cassa netto:
$-87.79M
1 W Prestazione:
+8.13%
1M Prestazione:
-4.05%
6M Prestazione:
-1.27%
1 anno Prestazione:
-12.94%
Intervallo 1D:
$2.69
$2.88
Intervallo di 1 settimana:
$2.405
$2.88
Portata 52W:
$2.095
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.725 | 250.56M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-31 | Iniziato | BTIG Research | Buy |
| 2019-02-01 | Downgrade | UBS | Buy → Neutral |
| 2019-01-04 | Iniziato | UBS | Buy |
| 2018-04-05 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Iniziato | Credit Suisse | Outperform |
| 2016-10-18 | Iniziato | Jefferies | Buy |
| 2016-10-18 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Ac Immune Sa Borsa (ACIU) Ultime notizie
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Average basic shares outstanding of AC Immune SA – HAN:IMR - TradingView
AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals - MarketBeat
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions (NASDAQ:ACIU) - Seeking Alpha
H.C. Wainwright reiterates AC Immune stock rating on trial data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
Top Penny Stocks To Watch In September 2026 - simplywall.st
AC Immune says ACI-7104 shows durable immunogenicity - The Pharma Letter
AC Immune SA (ACIU) Stock Price, News, Quote & History - Yahoo! Finance Canada
AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response - Benzinga
ACIU Looks 35.6% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
AC Immune reports positive phase 2 trial results for ACI-7104 - Investing.com Canada
AC Immune posts trial data for Parkinson’s drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports positive phase 2 trial results for Parkinson’s drug - Investing.com Australia
AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104 - TipRanks
Experimental Parkinson’s treatment from AC Immune (NASDAQ: ACIU) sparks immune response in early trial - Stock Titan
After 100 weeks, AC Immune's Parkinson's trial met its main safety and immune-response goals. - Stock Titan
AC Immune SA Share PriceACIU, RNS News, Articles, Quotes, & Charts (NASDAQ:ACIU) - Proactive financial news
AC Immune (ACIU) Slips 1.49% to $2.64 as Shares Sit Midway Between Key LevelsBlue Chip Entry Points - dars.gov.et
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus - TipRanks
AC Immune SA (NASDAQ: ACIU) Schedules October 2 Vote for Tom Graney's Board Nomination - Kalkine Media
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board - TipRanks
Parkinson's drug Fast Tracked as AC Immune (NASDAQ: ACIU) plans board changes - stocktitan.net
AC Immune Ltd (NASDAQ: ACIU) Share Price, ACIU Stock News, ACIU Share Price & Updates - kalkine.ca
AC Immune2026 Funding Rounds & List of Investors - Tracxn
AC Immune reports positive phase 1 data for ACI‑19764 - PharmaTimes
AC Immune stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor - pharmaphorum
AC (ACIU) Financial Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Market Price Moves 2.33% Higher on the DayConsensus Forecast Report - vinanet.vn
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - Benzinga
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study - AllSci
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance
AC Immune stock gains on early Phase 1 trial results - Investing.com India
AC Immune stock gains on early Phase 1 trial results By Investing.com - Investing.com Australia
AC Immune posts trial data for inflammatory drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports phase 1 safety data for NLRP3 inhibitor By Investing.com - Investing.com Nigeria
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764 - TipRanks
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - The Manila Times
AC Immune (NASDAQ: ACIU) advances NLRP3 pill into heart-risk trial - Stock Titan
AC (ACIU) Levels: Advances 0.39% to $2.58 in the Latest Reading; Chart View: $2.45 and $2.71 Define the Nearby Reference LevelsInside Day Breakout - vinanet.vn
AC Immune takes Parkinson's vaccine into US trials as Phase II data near - AllSci
Ac Immune Sa Azioni (ACIU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):